References
- Chen X, Peng D, She J, Cao L, Li Y, et al. Loss of ZG16 is regulated by miR-196a and contributes to stemness and progression of colorectal cancer. Oncotarget 7, 86695–86703, 2016.
- Jibawi A and Cade D: Colorectal cancer (CRC). Current Surgical Guidelines. Oxford: Oxford University Press, 2009.
- Brenner H, Kloor M, and Pox CP: Colorectal cancer. Lancet 383, 1490–1502, 2014.
- Haggar FA and Boushey RP: Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22, 191–197, 2009.
- Hsu HH, Chen MC, Baskaran R, Lin YM, Day CH, et al. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol 233, 5458–5467. 2017.
- Papaccio F, Paino F, Regad T, Papaccio G, Desiderio V, et al. Concise review: cancer cells, cancer stem cells, and mesenchymal stem cells: influence in cancer development. Stem Cells Transl Med 6, 2115–2125, 2017.
- Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochemical Pharmacology, 85, 1219–1226, 2013.
- Rebucci M, Peixoto P, Dewitte A, Wattez N, Nuncques MA, De, et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol 38, 189–200, 2011.
- Cao D, Qin S, Mu Y, and Zhong M: The role of MRP1 in the multidrug resistance of colorectal cancer. Oncol Lett 13, 2471, 2017.
- Kim HJ and Um JY: Association of a multidrug resistance 1 gene polymorphism and colorectal cancer in the Korean population. Orient Pharm Exp Med 13, 225–230, 2013.
- Barradas M, Gonos ES, Zebedee Z, Kolettas E, Petropoulou C, et al. Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp Cell Res 273, 127–137, 2002.
- Cheng Z, Guo J, Chen L, Luo N, Yang W, et al. Overexpression of TMEM158 contributes to ovarian carcinogenesis. J Exp Clin Cancer Res 34, 75, 2015.
- Iglesias D, Fernández-Peralta AM, Nejda N, Daimiel L, Azcoita MM, et al. RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis. Cancer Genet Cytogen 167, 138–144, 2006.
- Mohammed AS, Eguchi H, Wada S, Koyama N, Shimizu M, et al. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells. Exp Lung Res 38, 463–474, 2012.
- Verlinden I, Janssens J, Raus J, and Michiels L: Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast. Mol Carcinog 41, 197, 2004.
- Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, et al. Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosomes Cancer 45, 565–574, 2006.
- Wu Q, Yang Z, Nie Y, Shi Y, and Fan D: Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett 347, 159–166, 2014.
- Yang XJ, Li J, Sun CX, Zheng FY, and Hu LN: The effect of high frequency steep pulsed electric fields on in vitro and in vivo antitumor efficiency of ovarian cancer cell line skov3 and potential use in electrochemotherapy. J Exp Clin Canc Res 28, 53, 2009.
- Jemal A, Siegel R, Xu J, and Ward E: Cancer statistics, 2010. CA Cancer J Clin 63, 11, 2010.
- Silva J, Silva JM, Barradas M, Garcia JM, Dominguez G, et al. Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas. Mutat Res 594, 78–85, 2006.
- Player A, Abraham N, Burrell K, Bengone IO, Harris A, et al. Identification of candidate genes associated with triple negative breast cancer. Genes Cancer 8, 659, 2017.
- Evans WE and Mcleod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348, 538, 2003.
- Kartner N, Riordan JR, and Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221, 1285–1288, 1983.